Pluristem Therapeutics, Inc. is a biotechnology company, which engages in the provision of cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The company focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others. Its products include PLacental eXpanded, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PSTI
CUSIPN/A
Phone972-74-710-8607
Debt
Debt-to-Equity RatioN/A
Current Ratio4.58
Quick Ratio4.58
Price-To-Earnings
Trailing P/E Ratio-4.03
Forward P/E Ratio-5.38
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.85 million
Price / Sales50.18
Cash FlowN/A
Price / CashN/A
Book Value$0.31 per share
Price / Book4.16
Profitability
EPS (Most Recent Fiscal Year)($0.32)
Net Income$-27,810,000.00
Net MarginsN/A
Return on Equity-77.44%
Return on Assets-61.88%
Miscellaneous
Employees183
Outstanding Shares110,870,000
Market Cap$139.69 million
Pluristem Therapeutics (NASDAQ:PSTI) Frequently Asked Questions
What is Pluristem Therapeutics' stock symbol?
Pluristem Therapeutics trades on the NASDAQ under the ticker symbol "PSTI."
How were Pluristem Therapeutics' earnings last quarter?
Pluristem Therapeutics Inc. (NASDAQ:PSTI) released its quarterly earnings data on Thursday, May, 10th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.08. View Pluristem Therapeutics' Earnings History.
When is Pluristem Therapeutics' next earnings date?
What price target have analysts set for PSTI?
5 equities research analysts have issued 12-month price targets for Pluristem Therapeutics' stock. Their predictions range from $3.00 to $5.00. On average, they expect Pluristem Therapeutics' share price to reach $4.1250 in the next year. This suggests a possible upside of 219.8% from the stock's current price. View Analyst Price Targets for Pluristem Therapeutics.
What is the consensus analysts' recommendation for Pluristem Therapeutics?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pluristem Therapeutics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pluristem Therapeutics.
What are Wall Street analysts saying about Pluristem Therapeutics stock?
Here are some recent quotes from research analysts about Pluristem Therapeutics stock:
- 1. According to Zacks Investment Research, "PLURISTEM THERAPEUTICS INC. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from the human placenta, a non-controversial source, and not from embryonic stem cells. " (7/12/2018)
- 2. Maxim Group analysts commented, "Pluristem announced a joint project with Indiana University to evaluate PLX- R18 cells in Acute Radiation Syndrome (ARS). The study will be supported with $2.5M in grant funding, and data from the first year of the study will be used to further support a BLA filing." (4/23/2018)
Who are some of Pluristem Therapeutics' key competitors?
Some companies that are related to Pluristem Therapeutics include Nightstar Therapeutics (NITE), Replimune Group (REPL), Novavax (NVAX), Vericel (VCEL), Translate Bio (TBIO), NanoString Technologies (NSTG), Scholar Rock (SRRK), PDL BioPharma (PDLI), Neon Therapeutics (NTGN), Adverum Biotechnologies (ADVM), Cellular Biomedicine Group (CBMG), Surface Oncology (SURF), ADMA Biologics (ADMA), MeiraGTx (MGTX) and Nantkwest (NK).
Who are Pluristem Therapeutics' key executives?
Pluristem Therapeutics' management team includes the folowing people:
- Zami Aberman, Chairman & Co-Chief Executive Officer
- Yaky Yanay, President, Co-Chief Executive Officer & Director
- Erez Egozi, Chief Financial Officer, Secretary & Treasurer
- Racheli Ofir, Vice President-Research & Intellectual Property
- Efrat Kaduri, Manager-Investor & Public Relations
Has Pluristem Therapeutics been receiving favorable news coverage?
Media coverage about PSTI stock has been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pluristem Therapeutics earned a news impact score of 0.16 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 45.51 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for Pluristem Therapeutics.
Who are Pluristem Therapeutics' major shareholders?
Which institutional investors are selling Pluristem Therapeutics stock?
Which institutional investors are buying Pluristem Therapeutics stock?
How do I buy shares of Pluristem Therapeutics?
Shares of PSTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pluristem Therapeutics' stock price today?
One share of PSTI stock can currently be purchased for approximately $1.29.
How big of a company is Pluristem Therapeutics?
Pluristem Therapeutics has a market capitalization of $139.69 million and generates $2.85 million in revenue each year. The biotechnology company earns $-27,810,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Pluristem Therapeutics employs 183 workers across the globe.
How can I contact Pluristem Therapeutics?
Pluristem Therapeutics' mailing address is MATAM ADVANCED TECHNOLOGY PARK BUILDING NO. 5, HAIFA L3, 31905. The biotechnology company can be reached via phone at 972-74-710-8607 or via email at [email protected]
MarketBeat Community Rating for Pluristem Therapeutics (NASDAQ PSTI)
MarketBeat's community ratings are surveys of what our community members think about Pluristem Therapeutics and other stocks. Vote "Outperform" if you believe PSTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PSTI will underperform the S&P 500 over the long term. You may vote once every thirty days.
